BenevolentAI
ExitedBenevolentAI is a clinical-stage AI drug discovery company that combines advanced AI and machine learning with science to discover and develop novel and more effective medicines.
BenevolentAI has raised €92M across 1 funding round from 1 investor, most recently a round in Feb 2018. Based in London, UK; active in Healthtech. The company has exited (2021). Data as of 28 Oct 2026.
London, UKbenevolent.ai ↗
Total raised
€92M
€92,317,572
Funding rounds
1
Investors
1
distinct backers
Active since
2018-02
latest 2018-02
Funding by year
EUR raised per yearBenevolentAI — funding by year — interactive chart.
Data table
| BenevolentAI — funding by year | |
|---|---|
| 2018 | €92M |
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-02-01 | Other | €92M | Woodford Investment Management | View deal → |
Exit
Type
ipo
Date
Dec 2021
Value
€435M
Acquiror
—
Investors
1Related news
- Europe’s largest SPAC merger: UK’s BenevolentAI to list on Euronext Amsterdam via €1.5B SPAC dealsiliconcanals.com · 2021-12
- pehub.com
Similar companies
same sector or countryGlobal coverage: FundingData